Cargando…
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
Taking into account higher risk of severe coronavirus disease 2019 or death among patients with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in addition to waning immunity, booster dosing appears mandatory in this patient population. This review sought to provide reason...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674546/ https://www.ncbi.nlm.nih.gov/pubmed/35016032 http://dx.doi.org/10.1016/j.ejca.2021.12.011 |
_version_ | 1784615691737890816 |
---|---|
author | Barrière, Jérôme Carles, Michel Audigier-Valette, Clarisse Re, Daniel Adjtoutah, Zoubir Seitz-Polski, Barbara Gounant, Valérie Descamps, Diane Zalcman, Gérard |
author_facet | Barrière, Jérôme Carles, Michel Audigier-Valette, Clarisse Re, Daniel Adjtoutah, Zoubir Seitz-Polski, Barbara Gounant, Valérie Descamps, Diane Zalcman, Gérard |
author_sort | Barrière, Jérôme |
collection | PubMed |
description | Taking into account higher risk of severe coronavirus disease 2019 or death among patients with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in addition to waning immunity, booster dosing appears mandatory in this patient population. This review sought to provide reasonable evidence so as to assist oncologists in their daily practice, helping them decide when an anti-SARS-Cov2 antibody (Ab) dosage should be scheduled after a full two-dose vaccination and, if necessary, propose an early third dose (D3). Such D3 could apply to non-responder patients with anti-Spike (S) Abs titres <40 binding Ab unit (BAU)/mL. For lowresponder patients with anti-S Ab titres between 40 BAU/mL and 100/260 BAU/mL (suggested area of uncertainty), an early D3 may similarly be proposed. Nevertheless, this D3 could be administered in a less urgent manner, taking into account associated comorbidities and regional epidemic incidence rates. This latter strategy may comprise a monthly dosage of anti-S titres so as to better assess the kinetics of waning immunity. For responder patients with anti-S titres above 260 BAU/mL, we suggest to follow the recommendations outlined for the general population. Given this context, patients with anti-S titres above 1000 BAU/mL should be given the possibility to undergo anti-S titre control after three months, designed to assess rapid humoral waning immunity. We strongly recommend that patients with cancer be included into observational serological monitoring studies or clinical trials that are dedicated to severe immunocompromised patients without any humoral seroconversion after D3. |
format | Online Article Text |
id | pubmed-8674546 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86745462021-12-16 Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article Barrière, Jérôme Carles, Michel Audigier-Valette, Clarisse Re, Daniel Adjtoutah, Zoubir Seitz-Polski, Barbara Gounant, Valérie Descamps, Diane Zalcman, Gérard Eur J Cancer Review Taking into account higher risk of severe coronavirus disease 2019 or death among patients with cancer, as well as impaired immunogenicity after anti-SARS-CoV-2 vaccines, in addition to waning immunity, booster dosing appears mandatory in this patient population. This review sought to provide reasonable evidence so as to assist oncologists in their daily practice, helping them decide when an anti-SARS-Cov2 antibody (Ab) dosage should be scheduled after a full two-dose vaccination and, if necessary, propose an early third dose (D3). Such D3 could apply to non-responder patients with anti-Spike (S) Abs titres <40 binding Ab unit (BAU)/mL. For lowresponder patients with anti-S Ab titres between 40 BAU/mL and 100/260 BAU/mL (suggested area of uncertainty), an early D3 may similarly be proposed. Nevertheless, this D3 could be administered in a less urgent manner, taking into account associated comorbidities and regional epidemic incidence rates. This latter strategy may comprise a monthly dosage of anti-S titres so as to better assess the kinetics of waning immunity. For responder patients with anti-S titres above 260 BAU/mL, we suggest to follow the recommendations outlined for the general population. Given this context, patients with anti-S titres above 1000 BAU/mL should be given the possibility to undergo anti-S titre control after three months, designed to assess rapid humoral waning immunity. We strongly recommend that patients with cancer be included into observational serological monitoring studies or clinical trials that are dedicated to severe immunocompromised patients without any humoral seroconversion after D3. Elsevier Ltd. 2022-02 2021-12-16 /pmc/articles/PMC8674546/ /pubmed/35016032 http://dx.doi.org/10.1016/j.ejca.2021.12.011 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Barrière, Jérôme Carles, Michel Audigier-Valette, Clarisse Re, Daniel Adjtoutah, Zoubir Seitz-Polski, Barbara Gounant, Valérie Descamps, Diane Zalcman, Gérard Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title | Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title_full | Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title_fullStr | Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title_full_unstemmed | Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title_short | Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article |
title_sort | third dose of anti-sars-cov-2 vaccine for patients with cancer: should humoral responses be monitored? a position article |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674546/ https://www.ncbi.nlm.nih.gov/pubmed/35016032 http://dx.doi.org/10.1016/j.ejca.2021.12.011 |
work_keys_str_mv | AT barrierejerome thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT carlesmichel thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT audigiervaletteclarisse thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT redaniel thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT adjtoutahzoubir thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT seitzpolskibarbara thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT gounantvalerie thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT descampsdiane thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle AT zalcmangerard thirddoseofantisarscov2vaccineforpatientswithcancershouldhumoralresponsesbemonitoredapositionarticle |